Key Highlights

  • Phase 1a data presented at the ASRS meeting showed visual acuity and retinal thickness gains.
  • Candidate showed high intraocular retention with minimal systemic exposure.
  • Results support advancement into a Phase 1b/2 trial.
  • Early Phase 1b/2 data expected in the first half of 2027.

Kalaris Therapeutics (NASDAQ: KLRS) presented Phase 1a data at the ASRS meeting on July 17, 2026, showing significant gains in visual acuity and retinal thickness for its neovascular age-related macular degeneration candidate, TH103.

What Happened

The Phase 1a results indicated that the biologic candidate demonstrated high intraocular retention with minimal systemic exposure, according to the company.

These results are described as supporting the advancement of TH103 into a Phase 1b/2 trial.

Market Reaction

Kalaris Therapeutics, a small-cap company with a market value of approximately $104.2 million, traded near $4.38 per share, down $0.23, or 4.99%, according to the disclosed pipeline database.

Outlook

The company said early data from the planned Phase 1b/2 trial is anticipated in the first half of 2027.

What condition is TH103 being developed to treat?

TH103 is being developed for neovascular age-related macular degeneration (wet AMD).

What did the Phase 1a data show?

Data presented at the ASRS meeting on July 17, 2026 showed significant gains in visual acuity and retinal thickness, with high intraocular retention and minimal systemic exposure.

When is the next data readout for TH103 expected?

Early data from the planned Phase 1b/2 trial is anticipated in the first half of 2027.